Hemorrhoids, InternalPhase 2NCT04091763
Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal Disease
A Phase 2 study testing Polidocanol Injectable Foam and Rubber band ligation in people with Hemorrhoids, Internal, run by Universidade do Porto at 1 site in Portugal.
Trial summary
Background: Hemorrhoidal disease is a common benign condition seen frequently in clinical settings. Rubber band ligation and sclerotherapy have proven to be the office-based procedures of choice in hemorrhoidal disease, with various studies reporting rubber band ligation as being more effective but also more painful… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hemorrhoids, Internal
- What is being tested?
- Polidocanol Injectable Foam and Rubber band ligation
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 sitePortugal
- Study dates
- 1 Aug 2018to 1 Jul 2020
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients referred to proctologic consultation of Centro Hospitalar Universitário do Porto (CHUP) older than 18 years;
- Clinical diagnosis of hemorrhoidal disease grade I, II and III (Goligher's classification);
- Refractory to conservative management (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of no less than 4 weeks.
Who cannot join
- Hepatic cirrhosis;
- Pregnant or breast-feeding women;
- Known allergy to polidocanol
- Another perianal disease that can cause symptoms similar to hemorrhoidal disease;
- Concomitant presence of external hemorrhoidal disease and/or hemorrhoidal thrombosis;
- Office-based or surgical treatment for hemorrhoids within 6 months prior to inclusion;
Show all 10Show fewer
- Antiplatelet or hypocoagulant medication;
- Inherited bleeding disorders;
- Immunosuppressive states ;
- Inflammatory bowel disease.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Sclerotherapy With Polidocanol Foam Versus Rubber Band Ligation in the Treatment of First, Second and Third-Grade Hemorrhoidal Disease: a Randomized, Controlled Trial
Background: Hemorrhoidal disease is a common benign condition seen frequently in clinical settings. Rubber band ligation and sclerotherapy have proven to be the office-based procedures of choice in hemorrhoidal disease, with various studies reporting rubber band ligation as being more effective but also more painful and bleeding prone than sclerotherapy with liquid polidocanol. However, there are no studies comparing rubber band ligation and sclerotherapy with polidocanol foam, a new type of sclerosant agent that has already proved to be more effective and safer than liquid polidocanol in grade I hemorrhoidal disease.
The present study was designed to establish the clinical effectiveness and safety of sclerotherapy with polidocanol foam compared with rubber band ligation.
Read more
Methods: This randomized controlled trial includes patients with symptomatic hemorrhoidal disease grades I to III. The participants were randomly assigned (in a 1:1 ratio) to either rubber band ligation or sclerotherapy with polidocanol foam, stratified by grade of hemorrhoidal disease. During the intervention period the patients are submitted to one of the office-based procedures and, afterwards, in the follow-up period, evaluated every three months for a total period of one year.
The efficacy outcomes include symptom resolution, number of treatment sessions needed to achieve therapeutic success and evolution of hemorrhoidal disease grade in the intervention period and, during follow-up, recurrence incidence. Primary safety outcomes include the occurrence of any complication related to the office-based procedures.
Read the detailed description
INTRODUCTION Hemorrhoids are normal vascular structures in the anal canal, arising from a cushion of dilated arteriovenous channels and connective tissues, that drains into the superior and inferior hemorrhoidal veins. Their main function is to maintain anal continence, serve as a protection for the anal sphincters during the act of defecation and have a sensory function, allowing to differentiate liquids, solids or gases and to signal defecation.
The hemorrhoidal disease develops when the supporting tissues of hemorrhoidal cushions deteriorate due to various processes: abnormal venous dilation, vascular thrombosis, degenerative processes of collagen and fibroelastic tissue, distortion and rupture of anal subepithelial muscle, hyperperfusion of the hemorrhoidal plexus, inflammatory phenomena and hormonal changes (typical of pregnancy).
Hemorrhoidal disease occurs frequently in the adult population and a considerable number of patients are asymptomatic. Both sexes are similarly affected. The peak incidence occurs between 45-65 years, being rare before the age of 20.
Classification of hemorrhoidal disease corresponds to its position relative to the dentate line. External hemorrhoids are located below the dentate line and are covered by modified squamous epithelium, being richly innervated and therefore painful when there is associated thrombosis. On the contrary, internal hemorrhoids lie above the dentate line. Internal hemorrhoids are further classified based on their appearance and degree of prolapse according to the Goligher classification: grade I, without prolapse (they have the potential to bleed but are not visualized without the aid of an anoscope); grade II, prolapsed with defecation, but reduced spontaneously; grade III, prolapse with defecation requiring manual reduction and grade IV, prolapsed and non-reducible.
Since hemorrhoidal disease is a benign pathology, its treatment should be guided by the symptoms and the impact of the disease on quality of life. A prospective study by Pucher et al. developed and validated the Sodergren scale, which is based on a set of symptoms to assess the severity of hemorrhoidal disease. This scale can be used to assess the efficacy of treatment of haemorrhoids and the comparison of trials, consequently it is helpful in the choice of the best therapeutic option.
Treatment of hemorrhoidal disease can be divided into conservative measures, office-based procedures and surgical treatments.
First line therapy should be conservative and includes a set of lifestyle changes, dietary changes, laxative medication and phlebotonic and/or topical anti-inflammatory drugs. These measures produce beneficial effects and should be implemented in every grades of hemorrhoidal disease or in patients undergoing instrumental or surgical treatment.
The instrumental office-based treatment is usually indicated for hemorrhoidal disease grade I and II, thought it can also be used in grade III hemorrhoidal disease. It is aimed at decreasing hemorrhoidal vascularization, reducing redundant tissue and increasing hemorrhoidal rectal wall fixation to minimize prolapse. It includes rubber band ligation, sclerotherapy (liquid and foam agents), infrared photocoagulation, cryotherapy and radiofrequency ablation.
Rubber band ligation is the most commonly performed procedure in the office and is indicated for grade II and III internal hemorrhoids and works by causing hemorrhoid tissue necrosis and its fixation to the rectal mucosa. Complications associated with rubber band ligation include bleeding (ranging from mild to severe), pain, urinary symptoms, priapism, vagal symptoms, hemorrhoidal thrombosis, sepsis, fistulation or even death. Hemorrhage and pain are among the most frequent. Cumulatively, a success rate of 80% is observed with rubber band ligation.
Hemorrhoidal sclerosis is a procedure commonly used to treat grade I and II hemorrhoidal disease. It has also been used in internal grade III hemorrhoids, although in these cases there is little scientific evidence supporting its efficacy. In this technique a needle is introduced through an endoscope or anoscope and the sclerosing agent is injected into the hemorrhoid above the dentated line - Blanchard technique.
There are a variety of sclerosing agents such as 5% phenol in vegetable oil, quinine, tetradecyl sodium sulfate, sodium morphate or potassium aluminum sulfate and tannic acid (ALTA). More recently, a new sclerosing substance, polidocanol, a non-ionic detergent consisting of two components, a polar hydrophilic chain and a non-polar hydrophobic, started to be employed in the treatment of hemorrhoidal disease. The experience of its use in sclerotherapy comes mainly from the treatment of varicose veins and it can be used in its liquid or foam form. Several studies reported the efficacy of the use of sclerotherapy with liquid polidocanol in hemorrhoidal disease; it is considered a sclerosing agent with anesthetic properties, well tolerated, with low necrotic potential and a very promising agent for the treatment of grade I hemorrhoidal disease. The foam formation is based on the Tessari technique which uses a device that combines two syringes and a three-way tap in which the polidocanol is mixed with air under mechanical force ("Tourbillon technique"). This formulation allows for greater efficacy and use of lower doses of sclerosing agent since the volume will be greatly increased and hence also the area of contact with the vascular endothelium where the drug will exert its sclerosing action. The use of polidocanol foam in the treatment of varicose veins is safe and effective and has been shown to be superior to the use of liquid polidocanol. Its use is not indicated in cases of acute thromboembolism and allergy to polidocanol.
There is only one study showing the superiority of polidocanol foam compared to its liquid formulation in the treatment of grade I hemorrhoidal disease. In a recently published non-controlled study, 2000 patients with hemorrhoidal disease grades I to IV were treated with polidocanol foam and the authors concluded that this therapy was very successful, with 98% of the patients reporting satisfaction regarding bleeding control and prolapse reduction. Complications were rare and usually minor. There's a lack of studies comparing it with other ablative techniques.
The most common complications of sclerotherapy include mild anal discomfort and bleeding. However, the bleeding risk is lower compared to that observed with rubber band ligation. Rare complications include erectile dysfunction, mucosal ulceration, necrosis, prostatic abscess, retroperitoneal sepsis and transient bacteremia. Sclerotherapy is a valid alternative for the treatment of patients whose hemorrhage is the main symptom and where conservative therapy has not been effective, as well as for patients on anticoagulant medication, and for cirrhotic or immunocompromised patients.
There have been no comparative studies between polidocanol foam sclerotherapy and rubber band ligation.
With the present study, the investigators aim to fill a gap in the literature by evaluating the safety and efficacy in the treatment of hemorrhoidal disease with the seemingly most effective non-surgical office-based methods (rubber band ligation and sclerotherapy with polidocanol foam).
METHODS PARTICIPANTS AND ETHICAL ASPECTS Are included patients referred to proctologic consultation of Centro Hospitalar Universitário do Porto (CHUP) older than 18 years with symptomatic hemorrhoidal disease grade I, II and III (Goligher's classification) refractory to conservative management (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of no less than 4 weeks. All participants must have prior endoscopic study, at least recto-sigmoidoscopy, or complete colonoscopy if they are older than 50 years or younger with family history of colorectal cancer, colon adenomas, or suspected inflammatory bowel disease.
The study was approved by the ethics committee of CHUP. All the participants enrolled sign an informed consent.
STATISTICAL ANALYSIS Sample size was determined considering a power of 80% (type II error ß of 20%) and significance level α of 5% (type I error). The required number in each treatment was 44 patients. In order to safeguard against potential drop-outs, a sample size of 120 (60+60) patients was considered.
It was generated a 1:1 randomization sequence, stratified by for the degree of hemorrhoidal disease (Goligher's classification), to assign participants to each one of the therapeutic arms either sclerotherapy with polidocanol foam or rubber band ligation.
Since the two office-based therapies under study have completely different techniques and procedures, it is not possible to blind either the patient or the clinician who apply the treatment. Therefore, an open label study is being conducted.
VISITS AND DATA COLLECTION Demographic data such as age, sex, body mass index (BMI) are collected. In the first visit informed consent and an information brochure explaining the study and adequate dietary and behavioral care is provided.
For purposes of evaluating efficacy and safety, two distinct periods were considered: intervention and follow-up.
During the intervention period, when office-based treatments are performed, patients are observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed) and, during follow-up period, every 3 months, 3 weeks after the last session of treatment to evaluate recurrence of hemorrhoidal disease (maximum 1 year; 4 visits).
At all visits, a proctologic examination with anoscopy is performed and clinical evaluation is carried out by filling the Sodergren's scale of symptoms. The severity of bleeding is also evaluated.
INTERVENTION PERIOD AND TECHNICAL ASPECTS The required number of sessions of any of the office-based treatments (maximum of 3 sessions) is determined by clinical and anoscopy response i.e., if 3 weeks after the previous treatment the participant scores zero points in the Sodergren scale and has bleeding grade ≤1 or the anoscopy doesn't reveal significant hemorrhoidal disease, there is no place for additional instrumental therapy and the patient starts the follow-up period.
If there is therapeutic failure (participants that, at the end of three sessions of instrumental treatment, aggravate or maintain the initial Sodergren score and bleeding grade) or if there is a significant complication (moderate or severe) the patient's participation in the study ends and he is referred for treatment with other type of office-based procedure or surgery.
- Conditions
- Hemorrhoids, Internal
- Being tested
- Polidocanol Injectable Foam, Rubber band ligation
- Keywords
- Sclerotherapy, Rubber band ligation, Polidocanol foam, Hemorrhoidal disease
- Medical subject headings
- Hemorrhoids
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Polidocanol Injectable FoamDrug
Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.
If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.
Rubber band ligationDevice
Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.
If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.
| Study group | Role | What they receive |
|---|---|---|
| Polidocanol foam sclerotherapy | Experimental | 1. Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the "microbubbles" of the foam did not disintegrate);
2. Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;
3. Patients treated in a maximum of 3 sessions at 3 weeks intervals;
4. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;
5. In each session more than one hemorrhoid cushion could be treated. Receives: Drug: Polidocanol Injectable Foam |
| Rubber band ligation | Experimental | 1. Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;
2. A maximum of 3 sessions of ligation at 3-week intervals were performed;
3. More than 1 band per session could be applied. Receives: Device: Rubber band ligation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy outcome (therapeutic success)
Achievement of therapeutic success. Classified as:
- Complete (Sodergren score = 0 and bleeding grade ≤ 1);
- Partial (Sodergren score> 0 and bleeding grade > 1 but with improvement over initial score);
- Therapeutic failure (participants that, at the end of three sessions of instrumental treatment, aggravated or maintained the initial Sodergren score and bleeding grade).
Measured: Three to nine weeks (depending on the number of instrumental treatments performed)
Efficacy outcome (recurrence)
Recurrence of hemorrhoidal disease during the follow-up period (only for patients who have had some degree of therapeutic success). Classified as:
- Mild (Sodergren score and bleeding grade higher than the evaluation at the beginning of the follow-up period but lower than the initial ones without the need for instrumental or surgical intervention);
- Severe (Sodergren score and degree of hemorrhage ≥ the initial one requiring instrumental or surgical intervention).
Measured: One year (after the last office-based procedure)
Safety outcome
Complications resulting from the office-based procedures are recorded and classified as:
- Mild (e.g. pain/discomfort; pruritus; bright red blood on toilet paper/cleaning pad, hemorrhoidal thrombosis requiring only medical treatment);
- Moderate (e.g. external hemorrhoidal thrombosis requiring surgical intervention; bright red blood that drips in the toilet or clot expulsion not requiring blood transfusion, urgent hemostasis or urgent surgery): obliges the participant to be withdrawn from the study but do not endanger the patient's life or leave long term sequelae;
- Severe (e.g. sepsis; Fournier's gangrene; perineal abscess; bleeding with hemodynamic instability, transfusional need or urgent surgery; sexual impotence in man): obliges the participant to be withdrawn from the study and put the patient's life at risk or implies long-term sequelae.
Measured: Three to nine weeks (depending on the number of instrumental treatments performed)
Secondary outcomes (2)
Efficacy outcome (number of sessions)
Number of instrumental treatment sessions required to achieve therapeutic success.
Measured: Three to nine weeks (depending on the number of instrumental treatments performed)
Efficacy outcome (Goligher grade)
Evolution of the grade of hemorrhoidal disease (Goligher's classification).
Measured: Three to nine weeks (depending on the number of instrumental treatments performed)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2019
- Study start1 Aug 2018
- Primary completion1 Jul 2020
- Study completion1 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (30)Papers the sponsor has linked to this study.
- Other trials for Hemorrhoids, InternalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to either rubber band ligation or sclerotherapy with polidocanol foam, stratified by grade of hemorrhoidal disease
- Masking
- None (open label)
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidade do Porto
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Paulo Sérgio Durão Salgueiro, Universidade do Porto
- Investigators
- Paulo Salgueiro, MD, Principal investigator, Gastrenterologist
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04091763
- Sponsor's protocol ID
- 209117311
- Status last verified
- Aug 2020
- First submitted
- 4 Sep 2019
- Last updated
- 21 Aug 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sneider EB, Maykel JA. Diagnosis and management of symptomatic hemorrhoids. Surg Clin North Am. 2010 Feb;90(1):17-32, Table of Contents. doi: 10.1016/j.suc.2009.10.005.
PubMed 20109630Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012 May 7;18(17):2009-17. doi: 10.3748/wjg.v18.i17.2009.
PubMed 22563187Lohsiriwat V. Approach to hemorrhoids. Curr Gastroenterol Rep. 2013 Jul;15(7):332. doi: 10.1007/s11894-013-0332-6.
PubMed 23715885Riss S, Weiser FA, Schwameis K, Riss T, Mittlbock M, Steiner G, Stift A. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012 Feb;27(2):215-20. doi: 10.1007/s00384-011-1316-3. Epub 2011 Sep 20.
PubMed 21932016Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology. 1990 Feb;98(2):380-6. doi: 10.1016/0016-5085(90)90828-o.
PubMed 2295392Qureshi WA. Office management of hemorrhoids. Am J Gastroenterol. 2018 Jun;113(6):795-798. doi: 10.1038/s41395-018-0020-0. No abstract available.
PubMed 29487411Pucher PH, Qurashi M, Howell AM, Faiz O, Ziprin P, Darzi A, Sodergren MH. Development and validation of a symptom-based severity score for haemorrhoidal disease: the Sodergren score. Colorectal Dis. 2015 Jul;17(7):612-8. doi: 10.1111/codi.12903.
PubMed 25603811Sun Z, Migaly J. Review of Hemorrhoid Disease: Presentation and Management. Clin Colon Rectal Surg. 2016 Mar;29(1):22-9. doi: 10.1055/s-0035-1568144.
PubMed 26929748Hollingshead JR, Phillips RK. Haemorrhoids: modern diagnosis and treatment. Postgrad Med J. 2016 Jan;92(1083):4-8. doi: 10.1136/postgradmedj-2015-133328. Epub 2015 Nov 11.
PubMed 26561592Sandler RS, Peery AF. Rethinking What We Know About Hemorrhoids. Clin Gastroenterol Hepatol. 2019 Jan;17(1):8-15. doi: 10.1016/j.cgh.2018.03.020. Epub 2018 Mar 27.
PubMed 29601902Ganz RA. The evaluation and treatment of hemorrhoids: a guide for the gastroenterologist. Clin Gastroenterol Hepatol. 2013 Jun;11(6):593-603. doi: 10.1016/j.cgh.2012.12.020. Epub 2013 Jan 16. No abstract available.
PubMed 23333220Albuquerque A. Rubber band ligation of hemorrhoids: A guide for complications. World J Gastrointest Surg. 2016 Sep 27;8(9):614-620. doi: 10.4240/wjgs.v8.i9.614.
PubMed 27721924Cocorullo G, Tutino R, Falco N, Licari L, Orlando G, Fontana T, Raspanti C, Salamone G, Scerrino G, Gallo G, Trompetto M, Gulotta G. The non-surgical management for hemorrhoidal disease. A systematic review. G Chir. 2017 Jan-Feb;38(1):5-14. doi: 10.11138/gchir/2017.38.1.005.
PubMed 28460197Iyer VS, Shrier I, Gordon PH. Long-term outcome of rubber band ligation for symptomatic primary and recurrent internal hemorrhoids. Dis Colon Rectum. 2004 Aug;47(8):1364-70. doi: 10.1007/s10350-004-0591-2.
PubMed 15484351Acheson AG, Scholefield JH. Management of haemorrhoids. BMJ. 2008 Feb 16;336(7640):380-3. doi: 10.1136/bmj.39465.674745.80. No abstract available.
PubMed 18276714
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sclerotherapy With Polidocanol Foam Versus Rubber Band Ligation in the Treatment of First, Second and Third-Grade Hemorrhoidal Disease: a Randomized, Controlled Trial
- ClinicalTrials.gov ID
- NCT04091763
- Acronym / sponsor ID
- 209117311
- Conditions
- Hemorrhoids, Internal
- Keywords
- Sclerotherapy, Rubber band ligation, Polidocanol foam, Hemorrhoidal disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Universidade do PortoUniversity, hospital or other
- Study start
- 1 Aug 2018 (actual)
- Primary completion
- 1 Jul 2020 (actual)
- Study completion
- 1 Jul 2020 (actual)
- First posted
- 17 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Hemorrhoidal disease is a common benign condition seen frequently in clinical settings. Rubber band ligation and sclerotherapy have proven to be the office-based procedures of choice in hemorrhoidal disease, with various studies reporting rubber band ligation as being more effective but also more painful and bleeding prone than sclerotherapy with liquid polidocanol. However, there are no studies comparing rubber band ligation and sclerotherapy with polidocanol foam, a new type of sclerosant agent that has already proved to be more effective and safer than liquid polidocanol in grade I hemorrhoidal disease.
The present study was designed to establish the clinical effectiveness and safety of sclerotherapy with polidocanol foam compared with rubber band ligation.
Methods: This randomized controlled trial includes patients with symptomatic hemorrhoidal disease grades I to III. The participants were randomly assigned (in a 1:1 ratio) to either rubber band ligation or sclerotherapy with polidocanol foam, stratified by grade of hemorrhoidal disease. During the intervention period the patients are submitted to one of the office-based procedures and, afterwards, in the follow-up period, evaluated every three months for a total period of one year.
The efficacy outcomes include symptom resolution, number of treatment sessions needed to achieve therapeutic success and evolution of hemorrhoidal disease grade in the intervention period and, during follow-up, recurrence incidence. Primary safety outcomes include the occurrence of any complication related to the office-based procedures.
Detailed description
INTRODUCTION Hemorrhoids are normal vascular structures in the anal canal, arising from a cushion of dilated arteriovenous channels and connective tissues, that drains into the superior and inferior hemorrhoidal veins. Their main function is to maintain anal continence, serve as a protection for the anal sphincters during the act of defecation and have a sensory function, allowing to differentiate liquids, solids or gases and to signal defecation.
The hemorrhoidal disease develops when the supporting tissues of hemorrhoidal cushions deteriorate due to various processes: abnormal venous dilation, vascular thrombosis, degenerative processes of collagen and fibroelastic tissue, distortion and rupture of anal subepithelial muscle, hyperperfusion of the hemorrhoidal plexus, inflammatory phenomena and hormonal changes (typical of pregnancy).
Hemorrhoidal disease occurs frequently in the adult population and a considerable number of patients are asymptomatic. Both sexes are similarly affected. The peak incidence occurs between 45-65 years, being rare before the age of 20.
Classification of hemorrhoidal disease corresponds to its position relative to the dentate line. External hemorrhoids are located below the dentate line and are covered by modified squamous epithelium, being richly innervated and therefore painful when there is associated thrombosis. On the contrary, internal hemorrhoids lie above the dentate line. Internal hemorrhoids are further classified based on their appearance and degree of prolapse according to the Goligher classification: grade I, without prolapse (they have the potential to bleed but are not visualized without the aid of an anoscope); grade II, prolapsed with defecation, but reduced spontaneously; grade III, prolapse with defecation requiring manual reduction and grade IV, prolapsed and non-reducible.
Since hemorrhoidal disease is a benign pathology, its treatment should be guided by the symptoms and the impact of the disease on quality of life. A prospective study by Pucher et al. developed and validated the Sodergren scale, which is based on a set of symptoms to assess the severity of hemorrhoidal disease. This scale can be used to assess the efficacy of treatment of haemorrhoids and the comparison of trials, consequently it is helpful in the choice of the best therapeutic option.
Treatment of hemorrhoidal disease can be divided into conservative measures, office-based procedures and surgical treatments.
First line therapy should be conservative and includes a set of lifestyle changes, dietary changes, laxative medication and phlebotonic and/or topical anti-inflammatory drugs. These measures produce beneficial effects and should be implemented in every grades of hemorrhoidal disease or in patients undergoing instrumental or surgical treatment.
The instrumental office-based treatment is usually indicated for hemorrhoidal disease grade I and II, thought it can also be used in grade III hemorrhoidal disease. It is aimed at decreasing hemorrhoidal vascularization, reducing redundant tissue and increasing hemorrhoidal rectal wall fixation to minimize prolapse. It includes rubber band ligation, sclerotherapy (liquid and foam agents), infrared photocoagulation, cryotherapy and radiofrequency ablation.
Rubber band ligation is the most commonly performed procedure in the office and is indicated for grade II and III internal hemorrhoids and works by causing hemorrhoid tissue necrosis and its fixation to the rectal mucosa. Complications associated with rubber band ligation include bleeding (ranging from mild to severe), pain, urinary symptoms, priapism, vagal symptoms, hemorrhoidal thrombosis, sepsis, fistulation or even death. Hemorrhage and pain are among the most frequent. Cumulatively, a success rate of 80% is observed with rubber band ligation.
Hemorrhoidal sclerosis is a procedure commonly used to treat grade I and II hemorrhoidal disease. It has also been used in internal grade III hemorrhoids, although in these cases there is little scientific evidence supporting its efficacy. In this technique a needle is introduced through an endoscope or anoscope and the sclerosing agent is injected into the hemorrhoid above the dentated line - Blanchard technique.
There are a variety of sclerosing agents such as 5% phenol in vegetable oil, quinine, tetradecyl sodium sulfate, sodium morphate or potassium aluminum sulfate and tannic acid (ALTA). More recently, a new sclerosing substance, polidocanol, a non-ionic detergent consisting of two components, a polar hydrophilic chain and a non-polar hydrophobic, started to be employed in the treatment of hemorrhoidal disease. The experience of its use in sclerotherapy comes mainly from the treatment of varicose veins and it can be used in its liquid or foam form. Several studies reported the efficacy of the use of sclerotherapy with liquid polidocanol in hemorrhoidal disease; it is considered a sclerosing agent with anesthetic properties, well tolerated, with low necrotic potential and a very promising agent for the treatment of grade I hemorrhoidal disease. The foam formation is based on the Tessari technique which uses a device that combines two syringes and a three-way tap in which the polidocanol is mixed with air under mechanical force ("Tourbillon technique"). This formulation allows for greater efficacy and use of lower doses of sclerosing agent since the volume will be greatly increased and hence also the area of contact with the vascular endothelium where the drug will exert its sclerosing action. The use of polidocanol foam in the treatment of varicose veins is safe and effective and has been shown to be superior to the use of liquid polidocanol. Its use is not indicated in cases of acute thromboembolism and allergy to polidocanol.
There is only one study showing the superiority of polidocanol foam compared to its liquid formulation in the treatment of grade I hemorrhoidal disease. In a recently published non-controlled study, 2000 patients with hemorrhoidal disease grades I to IV were treated with polidocanol foam and the authors concluded that this therapy was very successful, with 98% of the patients reporting satisfaction regarding bleeding control and prolapse reduction. Complications were rare and usually minor. There's a lack of studies comparing it with other ablative techniques.
The most common complications of sclerotherapy include mild anal discomfort and bleeding. However, the bleeding risk is lower compared to that observed with rubber band ligation. Rare complications include erectile dysfunction, mucosal ulceration, necrosis, prostatic abscess, retroperitoneal sepsis and transient bacteremia. Sclerotherapy is a valid alternative for the treatment of patients whose hemorrhage is the main symptom and where conservative therapy has not been effective, as well as for patients on anticoagulant medication, and for cirrhotic or immunocompromised patients.
There have been no comparative studies between polidocanol foam sclerotherapy and rubber band ligation.
With the present study, the investigators aim to fill a gap in the literature by evaluating the safety and efficacy in the treatment of hemorrhoidal disease with the seemingly most effective non-surgical office-based methods (rubber band ligation and sclerotherapy with polidocanol foam).
METHODS PARTICIPANTS AND ETHICAL ASPECTS Are included patients referred to proctologic consultation of Centro Hospitalar Universitário do Porto (CHUP) older than 18 years with symptomatic hemorrhoidal disease grade I, II and III (Goligher's classification) refractory to conservative management (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of no less than 4 weeks. All participants must have prior endoscopic study, at least recto-sigmoidoscopy, or complete colonoscopy if they are older than 50 years or younger with family history of colorectal cancer, colon adenomas, or suspected inflammatory bowel disease.
The study was approved by the ethics committee of CHUP. All the participants enrolled sign an informed consent.
STATISTICAL ANALYSIS Sample size was determined considering a power of 80% (type II error ß of 20%) and significance level α of 5% (type I error). The required number in each treatment was 44 patients. In order to safeguard against potential drop-outs, a sample size of 120 (60+60) patients was considered.
It was generated a 1:1 randomization sequence, stratified by for the degree of hemorrhoidal disease (Goligher's classification), to assign participants to each one of the therapeutic arms either sclerotherapy with polidocanol foam or rubber band ligation.
Since the two office-based therapies under study have completely different techniques and procedures, it is not possible to blind either the patient or the clinician who apply the treatment. Therefore, an open label study is being conducted.
VISITS AND DATA COLLECTION Demographic data such as age, sex, body mass index (BMI) are collected. In the first visit informed consent and an information brochure explaining the study and adequate dietary and behavioral care is provided.
For purposes of evaluating efficacy and safety, two distinct periods were considered: intervention and follow-up.
During the intervention period, when office-based treatments are performed, patients are observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed) and, during follow-up period, every 3 months, 3 weeks after the last session of treatment to evaluate recurrence of hemorrhoidal disease (maximum 1 year; 4 visits).
At all visits, a proctologic examination with anoscopy is performed and clinical evaluation is carried out by filling the Sodergren's scale of symptoms. The severity of bleeding is also evaluated.
INTERVENTION PERIOD AND TECHNICAL ASPECTS The required number of sessions of any of the office-based treatments (maximum of 3 sessions) is determined by clinical and anoscopy response i.e., if 3 weeks after the previous treatment the participant scores zero points in the Sodergren scale and has bleeding grade ≤1 or the anoscopy doesn't reveal significant hemorrhoidal disease, there is no place for additional instrumental therapy and the patient starts the follow-up period.
If there is therapeutic failure (participants that, at the end of three sessions of instrumental treatment, aggravate or maintain the initial Sodergren score and bleeding grade) or if there is a significant complication (moderate or severe) the patient's participation in the study ends and he is referred for treatment with other type of office-based procedure or surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned to either rubber band ligation or sclerotherapy with polidocanol foam, stratified by grade of hemorrhoidal disease
| Arm | Type | Receives |
|---|---|---|
| Polidocanol foam sclerotherapy | Experimental | Drug: Polidocanol Injectable Foam1. Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the "microbubbles" of the foam did not disintegrate); 2. Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; 3. Patients treated in a maximum of 3 sessions at 3 weeks intervals; 4. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; 5. In each session more than one hemorrhoid cushion could be treated. |
| Rubber band ligation | Experimental | Device: Rubber band ligation1. Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position; 2. A maximum of 3 sessions of ligation at 3-week intervals were performed; 3. More than 1 band per session could be applied. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients referred to proctologic consultation of Centro Hospitalar Universitário do Porto (CHUP) older than 18 years;
- Clinical diagnosis of hemorrhoidal disease grade I, II and III (Goligher's classification);
- Refractory to conservative management (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of no less than 4 weeks.
Key exclusion criteria (10 listed)
- Hepatic cirrhosis;
- Pregnant or breast-feeding women;
- Known allergy to polidocanol
- Another perianal disease that can cause symptoms similar to hemorrhoidal disease;
- Concomitant presence of external hemorrhoidal disease and/or hemorrhoidal thrombosis;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Polidocanol Injectable FoamTwo distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period. If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery. | Drug | Polidocanol foam sclerotherapy |
| Rubber band ligationTwo distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period. If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery. | Device | Rubber band ligation |
Primary outcome
Efficacy outcome (therapeutic success)
Time frame: Three to nine weeks (depending on the number of instrumental treatments performed)
Achievement of therapeutic success. Classified as: 1. Complete (Sodergren score = 0 and bleeding grade ≤ 1); 2. Partial (Sodergren score> 0 and bleeding grade > 1 but with improvement over initial score); 3. Therapeutic failure (participants that, at the end of three sessions of instrumental treatment, aggravated or maintained the initial Sodergren score and bleeding grade).
Efficacy outcome (recurrence)
Time frame: One year (after the last office-based procedure)
Recurrence of hemorrhoidal disease during the follow-up period (only for patients who have had some degree of therapeutic success). Classified as: 1. Mild (Sodergren score and bleeding grade higher than the evaluation at the beginning of the follow-up period but lower than the initial ones without the need for instrumental or surgical intervention); 2. Severe (Sodergren score and degree of hemorrhage ≥ the initial one requiring instrumental or surgical intervention).
Safety outcome
Time frame: Three to nine weeks (depending on the number of instrumental treatments performed)
Complications resulting from the office-based procedures are recorded and classified as: 1. Mild (e.g. pain/discomfort; pruritus; bright red blood on toilet paper/cleaning pad, hemorrhoidal thrombosis requiring only medical treatment); 2. Moderate (e.g. external hemorrhoidal thrombosis requiring surgical intervention; bright red blood that drips in the toilet or clot expulsion not requiring blood transfusion, urgent hemostasis or urgent surgery): obliges the participant to be withdrawn from the study but do not endanger the patient's life or leave long term sequelae; 3. Severe (e.g. sepsis; Fournier's gangrene; perineal abscess; bleeding with hemodynamic instability, transfusional need or urgent surgery; sexual impotence in man): obliges the participant to be withdrawn from the study and put the patient's life at risk or implies long-term sequelae.
2 secondary outcomes
Efficacy outcome (number of sessions)
Time frame: Three to nine weeks (depending on the number of instrumental treatments performed)
Efficacy outcome (Goligher grade)
Time frame: Three to nine weeks (depending on the number of instrumental treatments performed)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2020.
- Background: PubMed 20109630Sneider EB, Maykel JA. Diagnosis and management of symptomatic hemorrhoids. Surg Clin North Am. 2010 Feb;90(1):17-32, Table of Contents. doi: 10.1016/j.suc.2009.10.005.
- Background: PubMed 22563187Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012 May 7;18(17):2009-17. doi: 10.3748/wjg.v18.i17.2009.
- Background: PubMed 23715885Lohsiriwat V. Approach to hemorrhoids. Curr Gastroenterol Rep. 2013 Jul;15(7):332. doi: 10.1007/s11894-013-0332-6.
- Background: PubMed 21932016Riss S, Weiser FA, Schwameis K, Riss T, Mittlbock M, Steiner G, Stift A. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012 Feb;27(2):215-20. doi: 10.1007/s00384-011-1316-3. Epub 2011 Sep 20.
- Background: PubMed 2295392Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology. 1990 Feb;98(2):380-6. doi: 10.1016/0016-5085(90)90828-o.
- Background: PubMed 29487411Qureshi WA. Office management of hemorrhoids. Am J Gastroenterol. 2018 Jun;113(6):795-798. doi: 10.1038/s41395-018-0020-0. No abstract available.
- Background: PubMed 25603811Pucher PH, Qurashi M, Howell AM, Faiz O, Ziprin P, Darzi A, Sodergren MH. Development and validation of a symptom-based severity score for haemorrhoidal disease: the Sodergren score. Colorectal Dis. 2015 Jul;17(7):612-8. doi: 10.1111/codi.12903.
- Background: PubMed 26929748Sun Z, Migaly J. Review of Hemorrhoid Disease: Presentation and Management. Clin Colon Rectal Surg. 2016 Mar;29(1):22-9. doi: 10.1055/s-0035-1568144.
- Background: PubMed 26561592Hollingshead JR, Phillips RK. Haemorrhoids: modern diagnosis and treatment. Postgrad Med J. 2016 Jan;92(1083):4-8. doi: 10.1136/postgradmedj-2015-133328. Epub 2015 Nov 11.
- Background: PubMed 29601902Sandler RS, Peery AF. Rethinking What We Know About Hemorrhoids. Clin Gastroenterol Hepatol. 2019 Jan;17(1):8-15. doi: 10.1016/j.cgh.2018.03.020. Epub 2018 Mar 27.
- Background: PubMed 23333220Ganz RA. The evaluation and treatment of hemorrhoids: a guide for the gastroenterologist. Clin Gastroenterol Hepatol. 2013 Jun;11(6):593-603. doi: 10.1016/j.cgh.2012.12.020. Epub 2013 Jan 16. No abstract available.
- Background: PubMed 27721924Albuquerque A. Rubber band ligation of hemorrhoids: A guide for complications. World J Gastrointest Surg. 2016 Sep 27;8(9):614-620. doi: 10.4240/wjgs.v8.i9.614.
- Individual participant dataSharing planned: No
Related trials for Hemorrhoids, Internal
Not yet recruiting
Auricular Indwelling Needles Added to Diosmin/Hesperidin for Grade I-II Internal Hemorrhoids With Heat-Toxin Syndrome
Internal Haemorrhoids
Not yet recruitingPhase 4
Evaluation of Polidocanol Foam Sclerotherapy in Symptomatic Internal Hemorrhoids: A Prospective Study
Internal Piles Sclerotherapy, Internal Hemorrhoids
Not yet recruiting
Laser Hemorrhoidoplasty Versus Open Hemorrhoidectomy for Postoperative Pain
Hemorrhoid
Not yet recruitingPhase 2
Comparing Rectal Artery Embolization and Surgery for Treatment of Bleeding Grade 2 and 3 Internal Hemorrhoids
Hemorrhoids Internal, Hemorrhoids Second Degree
Recruiting
HELO Trial: Energy-Based Therapies vs. Conventional Hemorrhoidectomy for Grade III Hemorrhoids
Hemorrhoids Third Degree, Internal Hemorrhoids
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paulo Salgueiro, MD principal investigator
Gastrenterologist
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Polidocanol Injectable Foam and Rubber band ligation in people with Hemorrhoids, Internal, run by Universidade do Porto at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy outcome (therapeutic success) (time frame: Three to nine weeks (depending on the number of instrumental treatments performed)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04091763, which also lists 30 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2020.